针对NMDA受体的小分子药物的新进展
Yue Zeng1,2,3, Zhi-Yan Qu1,2, Qian-Wen Zhu1
1State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
针对N-甲基-D-酸盐 (NMDA) 受体的小分子药物显示出治疗抑郁症和其他中枢神经系统疾病的前景. 最近的进展突出了NMDA受体调节的多样化化合物和广泛的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- N-甲基-D-酸盐 (NMDA) 受体是中枢神经系统 (CNS) 中重要的离子通道,调节神经发育和突触可塑性.
- 异常的NMDA受体活性与许多神经和精神疾病有关.
研究的目的:
- 审查针对NMDA受体的小分子调节器临床开发的最新进展.
- 探索NMDA受体向药物发现的治疗应用和未来方向.
主要方法:
- 对NMDA受体药理学近期临床发展的文献综述.
- 根据作用机制和治疗指示对NMDA受体调节剂的分类.
主要成果:
- 在开发用于各种中枢神经系统疾病的多种NMDA受体调节剂方面取得了显著进展.
- 抑郁症是一个关键的重点,在临床管道中含有胺和拉帕斯提内尔等化合物.
- 药物发现也在进行神经退行性疾病,疼痛,和中风.
结论:
- NMDA受体药理学已经成熟,显示出广泛的治疗潜力.
- 针对性调节NMDA受体为治疗具有挑战性的中枢神经系统疾病提供了有希望的途径.
- 对NMDA受体调节器的持续研究对于未来的药物发现至关重要.
更多相关视频
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
07:11Examination of Anatomical Features of Retinal Ganglion Cells Under N-methyl-D-aspartic Acid (NMDA)-induced Excitotoxicity
Published on: September 19, 2025
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Alzheimer's Disease: Treatment
Antidepressant Drugs: MAOIs and Other Agents
Neurochemical Transmission: Sites of Drug Action
